Publications
Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses." Ann Transl Med 7, no. 11 (2019): 244.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Empirical Likelihood for Estimating Equations with Nonignorably Missing Data." Stat Sin 24, no. 2 (2014): 723-747.
"An Empirical Bayes Method for Multivariate Meta-analysis with an Application in Clinical Trials." Commun Stat Theory Methods 43, no. 16 (2014): 3536-3551.
"Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology 5, no. 7 (2016): e1172153.
" Efficient test-based variable selection for high-dimensional linear models." J Multivar Anal 166 (2018): 17-31.
"Efficient Signal Inclusion With Genomic Applications." J Am Stat Assoc 114, no. 528 (2019): 1787-1799.
"Efficient Semiparametric Inference Under Two-Phase Sampling, With Applications to Genetic Association Studies." J Am Stat Assoc 112, no. 520 (2017): 1468-1476.
"Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
"Efficient Robust Regression via Two-Stage Generalized Empirical Likelihood." J Am Stat Assoc 108, no. 502 (2013): 644-655.
"Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Efficient Estimation of Semiparametric Transformation Models for the Cumulative Incidence of Competing Risks." J R Stat Soc Series B Stat Methodol 79, no. 2 (2017): 573-587.
"Efficient Estimation of Semiparametric Transformation Models for Two-Phase Cohort Studies." J Am Stat Assoc 109, no. 505 (2014): 371-383.
"Efficient Estimation of Nonparametric Genetic Risk Function with Censored Data." Biometrika 102, no. 3 (2015): 515-532.
"Efficient estimation of grouped survival models." BMC Bioinformatics 20, no. 1 (2019): 269.
"Efficient Estimation for Semiparametric Structural Equation Models With Censored Data." J Am Stat Assoc 113, no. 522 (2018): 893-905.
"Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics 73, no. 1 (2017): 114-123.
"Efficient augmentation and relaxation learning for individualized treatment rules using observational data." J Mach Learn Res 20 (2019).
"Effective SNP ranking improves the performance of eQTL mapping." Genet Epidemiol 44, no. 6 (2020): 611-619.
"Effective dimension reduction for sparse functional data." Biometrika 102, no. 2 (2015): 421-437.
" "DynTxRegime: A comprehensive package for analysis of dynamic treatment regimes (R).. v3.1 ed., 2017.
Dynamic treatment regimes: technical challenges and applications." Electron J Stat 8, no. 1 (2014): 1225-1272.
"Dynamic Treatment Regimes: Statistical Methods for Precision Medicine In Chapman & Hall/CRC Monographs on Statistics and Applied Probability. Boca Raton: Chapman and Hall/CRC, 2019.
Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Dynamic treatment regimes." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016.
"Dynamic spatial pattern recognition in count data." In New Developments in Statistical Modeling, Inference and Application, 185-202. New York: Springer, 2016.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"dtrSurv: Dynamic Treatment Regimes for Survival Analysis (R). 1.1 ed., 2020.
DTRlearn: Learning Algorithms for Dynamic Treatment Regimes (R). 1.3 ed., 2018.
DTIPrep: quality control of diffusion-weighted images." Front Neuroinform 8 (2014): 4.
"Drug safety in spontaneous reports, observational databases, and clinical trials: Can we do better?., 2011.
DOVE: Durability of Vaccine Efficacy. v1.2 ed., 2021.
Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"doublyRobust: Doubly robust estimation for monotonely coarsened data in longitudinal studies with dropout and/or incomplete data (R).. 2nd ed., 2013.
Doubly Robust Learning for Estimating Individualized Treatment with Censored Data." Biometrika 102, no. 1 (2015): 151-168.
"Doubly robust inference when combining probability and non-probability samples with high dimensional data." J R Stat Soc Series B Stat Methodol 82, no. 2 (2020): 445-465.
"DOUBLY ROBUST ESTIMATION OF OPTIMAL TREATMENT REGIMES FOR SURVIVAL DATA-WITH APPLICATION TO AN HIV/AIDS STUDY." Ann Appl Stat 11, no. 3 (2017): 1763-1786.
"Double Sparsity Kernel Learning with Automatic Variable Selection and Data Extraction." Stat Interface 11, no. 3 (2018): 401-420.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Domain selection for the varying coefficient model via local polynomial regression." Comput Stat Data Anal 83 (2015): 236-250.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Discussion of the paper "Clustering Random Curves Under Spatial Interdependence with Application to Service Accessibility" by Jiang and Serban." Technometrics 54, no. 2 (2012): 129-133.
"Discussion of the Paper by R. L. Prentice and Y. Huang - Optimal Designs and Efficient Inference for Biomarker Studies." Stat Theory Relat Fields 2, no. 1 (2018): 21-22.
"Discussion of Laber et al. "Optimal treatment allocations in space and time for on-line control of an emerging infectious disease"." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 779-780.
"Discussion of "Connections Between Survey Calibration Estimators and Semiparametric Models for Incomplete Data" by T. Lumley, P.A. Shaw & J.Y. Dai." Int Stat Rev 79, no. 2 (2011): 221-223.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
" DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Diagnostic Measures for the Cox Regression Model with Missing Covariates." Biometrika 102, no. 4 (2015): 907-923.
" Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Determining the Number of Latent Factors in Statistical Multi-Relational Learning." J Mach Learn Res 20 (2019).
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Designing penalty functions in high dimensional problems: The role of tuning parameters." Electron J Stat 10, no. 2 (2016): 2312-2328.
" Design of phase III clinical trials." In Oncology Clinical Trials: Successful Design, Conduct, and Analysis. New York: Demos Medical Publishing, LLC, 2010.
"Design of Phase II Non-inferiority Trials." Contemp Clin Trials Commun 7 (2017): 23-27.
" Deep advantage learning for optimal dynamic treatment regime." Stat Theory Relat Fields 2, no. 1 (2018): 80-88.
" Data fraud in clinical trials." Clin Investig (Lond) 5, no. 2 (2015): 161-173.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"CTD Systems (Java)., 2017.
cSFM: Covariate-adjusted skewed functional model (R).. 1.1 ed., 2014.
CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS). 1.0 ed., 2019.
CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
"Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach." JMIR Hum Factors 6, no. 2 (2019): e12700.
" A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
"Cook's Distance Measures for Varying Coefficient Models with Functional Responses." Technometrics 57, no. 2 (2015): 268-280.
"Continual reassessment method with regularization in phase I clinical trials." J Biopharm Stat 30, no. 6 (2020): 964-978.
"A Consistent Information Criterion for Support Vector Machines in Diverging Model Spaces." J Mach Learn Res 17, no. 16 (2016): 1-26.
"Consistent high-dimensional Bayesian variable selection via penalized credible regions." J Am Stat Assoc 107, no. 500 (2012): 1610-1624.
"Consistent Group Identification and Variable Selection in Regression with Correlated Predictors." J Comput Graph Stat 22, no. 2 (2013): 319-340.
"Consistency and overfitting of multi-omics methods on experimental data." Brief Bioinform 21, no. 4 (2020): 1277-1284.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"A Confidence Region Approach to Tuning for Variable Selection." J Comput Graph Stat 21, no. 2 (2012): 295-314.
"CONCUR: Kernel-based association test for copy number variation (CNV) aggregate analysis (R)., 2020.
Concordance-Assisted Learning for Estimating Optimal Individualized Treatment Regimes." J R Stat Soc Series B Stat Methodol 79, no. 5 (2017): 1565-1582.
"Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data." J Comput Graph Stat 27, no. 1 (2018): 48-58.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"Composite large margin classifiers with latent subclasses for heterogeneous biomedical data." Stat Anal Data Min 9, no. 2 (2016): 75-88.
"Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates." Bioinformatics 32, no. 1 (2016): 50-7.
"Complete effect-profile assessment in association studies with multiple genetic and multiple environmental factors." Genet Epidemiol 39, no. 2 (2015): 122-33.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"Comparison of operational characteristics for binary tests with clustered data." Stat Med 34, no. 15 (2015): 2325-33.
"A Comparison of Monte Carlo Methods for Computing Marginal Likelihoods of Item Response Theory Models." J Korean Stat Soc 48, no. 4 (2019): 503-512.
"Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials." Stat Med 36, no. 3 (2017): 403-415.
"Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"